Literature DB >> 11343868

Synaptophysin and GAP-43 mRNA levels in the hippocampus of subjects with schizophrenia.

M J Webster1, C Shannon Weickert, M M Herman, T M Hyde, J E Kleinman.   

Abstract

Synaptophysin and growth associated protein-43 (GAP-43) are synaptic proteins colocalized to the presynaptic terminal, and involved in regulating transmitter release and synaptic plasticity. Recent studies have proposed an alteration in the number of synapses in the brains of individuals with schizophrenia. As a corollary, we hypothesized that there may be an alteration in the level of mRNAs that code for synaptic proteins in brains of patients with schizophrenia. Using in situ hybridization, we investigated the levels of synaptophysin and GAP-43 mRNA in the medial temporal lobe of 10 normal subjects, 11 subjects with schizophrenia and 10 psychiatric control subjects. Synaptophysin mRNA levels were significantly reduced in several hippocampal subfields in both the schizophrenic and psychiatric control groups. GAP-43 mRNA levels were not significantly reduced in either group. The implications of these findings are discussed in relation to neuroleptic treatment and the pathophysiology of mental illness.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11343868     DOI: 10.1016/s0920-9964(00)00052-9

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  16 in total

Review 1.  Understanding the pathology of schizophrenia: recent advances from the study of the molecular architecture of postmortem CNS tissue.

Authors:  B Dean
Journal:  Postgrad Med J       Date:  2002-03       Impact factor: 2.401

Review 2.  The hippocampus in schizophrenia: a review of the neuropathological evidence and its pathophysiological implications.

Authors:  Paul J Harrison
Journal:  Psychopharmacology (Berl)       Date:  2004-03-06       Impact factor: 4.530

3.  Lack of change in markers of presynaptic terminal abundance alongside subtle reductions in markers of presynaptic terminal plasticity in prefrontal cortex of schizophrenia patients.

Authors:  Samantha J Fung; Sinthuja Sivagnanasundaram; Cynthia Shannon Weickert
Journal:  Biol Psychiatry       Date:  2011-01-01       Impact factor: 13.382

4.  Gene expression of metabolic enzymes and a protease inhibitor in the prefrontal cortex are decreased in schizophrenia.

Authors:  Marquis P Vawter; Cynthia Shannon Weickert; Erick Ferran; Mitsuyuki Matsumoto; Kevin Overman; Thomas M Hyde; Daniel R Weinberger; William E Bunney; Joel E Kleinman
Journal:  Neurochem Res       Date:  2004-06       Impact factor: 3.996

5.  Reduced DTNBP1 (dysbindin-1) mRNA in the hippocampal formation of schizophrenia patients.

Authors:  Cynthia Shannon Weickert; Debora A Rothmond; Thomas M Hyde; Joel E Kleinman; Richard E Straub
Journal:  Schizophr Res       Date:  2007-10-24       Impact factor: 4.939

6.  Early parental deprivation in the marmoset monkey produces long-term changes in hippocampal expression of genes involved in synaptic plasticity and implicated in mood disorder.

Authors:  Amanda J Law; Qi Pei; Mary Walker; Helen Gordon-Andrews; Cyndi Shannon Weickert; Joram Feldon; Christopher R Pryce; Paul J Harrison
Journal:  Neuropsychopharmacology       Date:  2008-07-09       Impact factor: 7.853

7.  Upregulation of NRG-1 and VAMP-1 in human brain aggregates exposed to clozapine.

Authors:  Gursharan Chana; Ginger Lucero; Shahid Salaria; Jean Lozach; Pinyi Du; Christopher Woelk; Ian Everall
Journal:  Schizophr Res       Date:  2009-06-07       Impact factor: 4.939

8.  Molecular evidence for decreased synaptic efficacy in the postmortem olfactory bulb of individuals with schizophrenia.

Authors:  Chijioke N Egbujo; Duncan Sinclair; Karin E Borgmann-Winter; Steven E Arnold; Bruce I Turetsky; Chang-Gyu Hahn
Journal:  Schizophr Res       Date:  2015-08-07       Impact factor: 4.939

9.  The methylazoxymethanol acetate (MAM-E17) rat model: molecular and functional effects in the hippocampus.

Authors:  Eva Hradetzky; Thomas M Sanderson; Tsz M Tsang; John L Sherwood; Stephen M Fitzjohn; Viktor Lakics; Nadia Malik; Stephanie Schoeffmann; Michael J O'Neill; Tammy Mk Cheng; Laura W Harris; Hassan Rahmoune; Paul C Guest; Emanuele Sher; Graham L Collingridge; Elaine Holmes; Mark D Tricklebank; Sabine Bahn
Journal:  Neuropsychopharmacology       Date:  2011-09-28       Impact factor: 7.853

10.  Rethinking schizophrenia in the context of normal neurodevelopment.

Authors:  Vibeke S Catts; Samantha J Fung; Leonora E Long; Dipesh Joshi; Ans Vercammen; Katherine M Allen; Stu G Fillman; Debora A Rothmond; Duncan Sinclair; Yash Tiwari; Shan-Yuan Tsai; Thomas W Weickert; Cynthia Shannon Weickert
Journal:  Front Cell Neurosci       Date:  2013-05-15       Impact factor: 5.505

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.